- Aurora Cannabis receives EU-GMP certification for its Aurora River processing facility
- The certification marks the company’s third facility with EU-GMP qualification
- Aurora also announced the reversal of a temporary sales suspension in Germany relating to a ‘proprietary step’ in its production process
- The company’s shares are currently up 0.4 per cent to C$2.51, with a market cap of C$2.75 billion
Aurora Cannabis has received European Union Good Manufacturing Practice (EU-GMP) certification for its Aurora River production facility in Bradford, Ontario.
The certification is granted to companies that demonstrate significant quality and consistency in their manufacturing processes.
EU-GMP certification is required for the export of cannabis products to the majority of European markets.
“The EU GMP certification of our River facility further validates our strategy focused on purpose-built facilities, designed and constructed exclusively for the production of high-quality, pharmaceutical grade cannabis,” said Aurora CEO, Terry Booth.
“I congratulate our team on successfully working with regulators and licensing bodies to ensure Aurora’s facilities and products are in accordance with local and international standards that will allow for greater access to the highest quality medical cannabis products to patients who need them.”
The Aurora River facility is designed for large-scale and high-quality production. It offers a cultivation capacity of 28,000 kg per year, with 17 fully-planted, independently climate-controlled grow rooms.
It joins two other facilities in achieving certification: Aurora Mountain in Alberta, with 4,800 kg per year production capacity; and Aurora Ridge in Ontario, with a production capacity of 7,000 kg per year.
The company also announced the reversal of a temporary sales suspension in Germany, following approval from local regulators.
According to an article published by Marijuana Business Daily, Aurora Cannabis’ products were unavailable from December 2019 pending a review by health authorities of a ‘proprietary step’ in its production process, allegedly related to a method used to ensure the shelf life of the flower.
With the green light for sales now in place, Aurora will fulfil its existing orders in Germany, ensuring local patients have immediate access to medicine from their preferred pharmacy.
Aurora Cannabis shares are currently up 0.4 per cent to C$2.51, with a market cap of C$2.75 billion.